Kyverna Therapeutics, Inc.
KYTX
$1.82
-$0.01-0.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 95.09% | 180.57% | 185.84% | 158.02% | 142.86% |
| Gross Profit | -95.09% | -180.57% | -185.84% | -158.02% | -152.96% |
| SG&A Expenses | 145.80% | 171.90% | 117.16% | 111.49% | 111.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 105.08% | 178.68% | 170.21% | 146.90% | 136.03% |
| Operating Income | -105.08% | -178.68% | -170.21% | -146.90% | -143.61% |
| Income Before Tax | -81.40% | -163.48% | -137.71% | -139.55% | -143.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -81.40% | -163.48% | -137.71% | -139.55% | -143.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.40% | -163.48% | -137.71% | -139.55% | -143.26% |
| EBIT | -105.08% | -178.68% | -170.21% | -146.90% | -143.61% |
| EBITDA | -105.78% | -128.69% | -- | -149.31% | -143.70% |
| EPS Basic | 96.66% | 96.17% | 96.69% | 90.71% | -62.39% |
| Normalized Basic EPS | 96.41% | 96.36% | 96.69% | 91.09% | -62.39% |
| EPS Diluted | 96.66% | 96.17% | 96.69% | 90.71% | -62.39% |
| Normalized Diluted EPS | 96.41% | 96.36% | 96.69% | 91.09% | -62.39% |
| Average Basic Shares Outstanding | 5,327.03% | 6,776.34% | 7,088.81% | 2,478.32% | 49.79% |
| Average Diluted Shares Outstanding | 5,327.03% | 6,776.34% | 7,088.81% | 2,478.32% | 49.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |